Crinetics Pharmaceuticals, Inc.
CRNX
$37.48
$0.571.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -127.85M | -122.82M | -130.09M | -115.64M | -96.77M |
| Total Depreciation and Amortization | 1.16M | 994.00K | 1.01M | 959.00K | 925.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.18M | 19.65M | 19.86M | 22.23M | 16.93M |
| Change in Net Operating Assets | -26.20M | 9.27M | -1.50M | 6.60M | -9.54M |
| Cash from Operations | -124.70M | -92.90M | -110.72M | -85.85M | -88.45M |
| Capital Expenditure | -820.00K | -458.00K | -863.00K | -3.20M | -1.24M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -251.54M | 57.57M | 165.67M | 41.16M | -84.72M |
| Cash from Investing | -252.36M | 57.11M | 164.81M | 37.95M | -85.96M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 390.45M | 26.04M | 3.08M | 7.06M | 4.44M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -578.00K | -- | -- | -- | -- |
| Cash from Financing | 389.88M | 26.04M | 3.08M | 7.06M | 4.44M |
| Foreign Exchange rate Adjustments | -8.00K | -106.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.81M | -9.87M | 57.18M | -40.84M | -169.98M |